Chapter 109 - Infrainguinal disease surgical treatment Flashcards

1
Q

Risk of severe clinical deterioration of a claudicant in 3-5 years

A

20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Risk of major amputation in claudicant in 3-5 years

A

5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

European consensus document definition of CLI

A

1) persistent recurrent ischemic rest pain requiring opioid x 2 weeks 2) ankle pressure < 50 3) toe pressure < 30 4) ulceration or gangrene of foot/toes 5) absent pedal pulse in diabetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Wolfe and Wyatt on subcritical and critical CLI definition

A

Subcritical: rest pain Ankle pressure > 40 (27% limb alive at 1 year without surgery) Critical: rest pain/tissue loss ankle < 40 (5% limb alive at 1 year)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Perioperative MI for LE arterial reconstruction

A

2-6.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Venous conduit cutoff

A

2-3 mm - must dilate well 3 mm minimum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Significant lesion based on pressure gradient

A

10 mmHg OR 15% drop after papaverine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When should GSV bypass not be used as a patch simultaneously

A

1) thickened arterial wall 2) small donor artery 3) small vein conduit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Linton’s technique

A

Vein patch first then bypass proximal anast on top of the patch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Isolated popliteal target definition

A

1) 5 cm long popliteal 2) only geniculate collaterals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Patency of isolated popliteal bypass target at 5 years

A

50% primary 74% secondary patency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bypass outflow principle in patient with tissue loss

A

inline flow with pulsatile foot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When to choose pedal bypass over proximal peroneal

A

1) adequate conduit 2) frank tissue loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

vein crossing over the proximal PFA

A

Lateral femoral circumflex vein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Lateral approach to PFA key steps

A

1) incision in upper thigh lateral to sartorius 2) sartorius and SFA retracted medially 3) raphe between adductor longus and vastus medialis incised to expose PFA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Branches of the profunda femoris artery

A

medial and lateral circumflex femoral artery 1st, 2nd, 3rd perforating branches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Chance of needing contralateral GSV in future operation

A

20-25% no merit in saving unless already symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Miller cuff

A

prosthetic to a circumferential cuff of vein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Taylor patch

A

Patching open the hood with vein to make it bigger and more elastic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

St. Mary’s boot

A

the end of one end of the vein patch sews onto the side of another to create a cuff

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

patency of heparin-bound dacron vs PTFE for above knee bypass at 3 year

A

55% vs 42% dacron better

22
Q

below knee bypass with PTFE +/- vein cuff 2 year patency

A

52% vs 29% vein patch/cuff works

23
Q

Human umbilical vein for bypass

A

Thicker and cumbersome to handle and risk of aneurysmal degeneration

24
Q

Distal AV fistula to increase bypass flow velocity

A

no clear evidence

25
Q

Heparin bonded PTFE pharmacodynamic

A

biologically active heparin up to 12 weeks effect in animals benefit up to 180 days not clear in humans

26
Q

Carmeda bioactive surface (CBAS)

A

heparin bonded material

27
Q

Solution to dilate venous conduit

A

1000 Units heparin and 60 mg of papaverine in 50-60 ml of autologous blood (better preserve graft endothelium) use saline instead for arm vein because thinner and harder to see leaks otherwise

28
Q

Types of valvulotomes

A

Mills - radial cutting Hall and LeMaitre - fixed diameter circumferential blades

29
Q

Completion assessment of the bypass

A

1) distal pulse palpation and Doppler flow +/- manual graft compression 2) completion arteriography 3) intraoperative duplex +/- papaverine 4) angioscope

30
Q

Post-bypass arteriography chance of correcting

A

8-27% patency increase from 72% to 100% in two weeks

31
Q

Completion duplex ultrasound chance for revision and downsides

A

12% no technician and equipment available

32
Q

Angioscope benefit

A

Assess arm vein conduits as well as for completion of valve lysis

33
Q

Factors associated with reduced graft patency

A

1) small conduit < 3mm 2) poor run off 3) high outflow resistance 4) ESRD

34
Q

Define primary patency, assisted primary and secondary

A

Primary = patent continuously without any action Assisted primary = intervention but was never occluded (reflection of the surveillance and timely reintervention) Secondary = thrombosed but revived (reflection of surgeon persistence)

35
Q

Reversed vein vs in situ bypass in patency

A

same although for small vein < 3mm, in situ seems to be better but not significant

36
Q

Comparison of primary patency for above knee fem-pop bypass conduit types

A

Comparable TABLE 109.3

37
Q

Comparison of primary/secondary patency for below knee fem-pop bypass conduit types

A

Vein much better than PTFE TABLE 109.4

38
Q

Comparison of patency for infrapopliteal grafts (tibial bypass)

A

Vein much better than arm vein and PTFE TABLE 109.5

39
Q

Pedal bypass results

A

TABLE 109.6

40
Q

BASIL key point

A

1) patients who live > 2 years will benefit from bypass first strategy 2) vein better than prosthetic for CLTI 3) angioplasty then bypass vs bypass, primary bypass better for amputation free survival

41
Q

Treatment for WIfI clinical stage 4 patients

A

Open bypass

42
Q

Factors that increase the risk of graft failure

A

1) impaired ambulatory status at presentation 2) DM 3) ESRD 4) gangrene 5) prior vascular intervention combination worst

43
Q

FINNVASC score system

A

1) DM 2) foot gangrene 3) CAD 4) urgent operation risk on scale of 1-4 based on sum of all points externally validated

44
Q

PREVENT III prediction model

A

1) ESRD HD 4 points 2) tissue loss 3 points 3) age > 75 2 points 4) CAD 1 point low risk < 3 pt medium 4-7 high > 8 externally validated

45
Q

BASIL stratification system

A

1) tissue loss 2) BMI 3) serum creatinine 4) Bollinger score 5) age 6) smoking 7) CAD 8) ankle pressure complex model not externally validated

46
Q

PREVENT III complication rates

A

death 2.7% MI 4.7% major amputation 1.8% graft occlusion 5.2% major wound complication 4.8% graft hemorrhage 0.4% Late complications 1) lymphedema 2) graft infection 3) graft anuerysm 4) graft stenosis

47
Q

Rate of graft threatening stenosis in 2 years from vein grafts

A

1/3

48
Q

Signs of a threatened graft

A

1) PSV > 300 2) velocity ratio > 3.5 - 4 3) PSV < 45 4) drop in ABI > 0.15

49
Q

Types of stenosis in vein graft follow up

A

Solitary stenosis 80% multiple focal lesions 15-20% Diffuse long segment narrowing 3-5%

50
Q

Principles of PTA of stenotic graft lesions after bypass

A

1) > 6 month old grafts responds better 2) cutting balloon beneficial 3) no stenting 4) recurrence rate higher than open revision so need surveillance

51
Q

Surgical open revision of bypass stenosis

A

1) patch 2) interposition bypass 3) reciting proximal anast 4) jump graft